Pricing Log in Create free account

Kymera Therapeutics, Inc. (KYMR) vs Summit Therapeutics PLC (SMMT)

Kymera Therapeutics, Inc. and Summit Therapeutics PLC are both Biotechnology companies. Kymera Therapeutics, Inc. and Summit Therapeutics PLC are of similar size ($11.3B and $10.9B). Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against −61.0%. Across the 14 metrics below, Kymera Therapeutics, Inc. leads on 11 and Summit Therapeutics PLC on 3.

Valuation

Metric KYMR SMMT Biotechnology median
P/E n/m n/m 10.26
P/S 119.82 15,883.80 9.18
P/B 7.79 17.78 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 110.58 15,045.51 8.98
Earnings yield (2.88%) (7.78%) (34.89%)
Free cash flow yield (2.30%) (4.11%) (24.52%)

Profitability

Metric KYMR SMMT Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (27.29%) (192.50%) (50.12%)
Return on assets (24.36%) (159.09%) (45.60%)
Return on invested capital (39.30%) 0.00% 0.00%

Growth

Metric KYMR SMMT Biotechnology median
Revenue growth (TTM) 134.84% (61.03%) 6.26%
EPS growth (last fiscal year) (23.83%) (364.52%) 29.88%
Revenue growth, 5-year CAGR 2.87% (46.49%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KYMR SMMT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.13 6.96 4.89
Net debt to EBITDA 2.42 0.65 1.01

Dividend

Metric KYMR SMMT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KYMR SMMT Biotechnology median
Market cap 10.94b 11.32b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack